Search
GI Cancer
S2433
Randomized Phase III Study of Second-Line Chemotherapy with or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma
A212101
Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients With Newly Diagnosed Colorectal Cancer
A232402CD
PAGODA: RANDOMIZED TRIAL OF A PROACTIVE GRADUATED DOSE MODIFICATION ALGORITHM FOR FOLFOX CHEMOTHERAPY TO PREVENT UNPLANNED DELAYS
NRG GI011 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Phase III Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC)
NSABP FC-13 **ARMS 1 and 2 Only**
A Phase II Platform Study to Evaluate Treatment with Cemiplimab Monotherapy or Cemiplimab plus Fianlimab or Other Novel Combinations in Patients with Colorectal Cancer with Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
S2417CD
A Pragmatic Randomized Controlled Trial To Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance
S2408 (MBMC Only) ***Temporarily Closed to Enrollment***
A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
EAQ222CD
Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients
A022102 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
RANDOMIZED PHASE III TRIAL OF MFOLFIRINOX +/- NIVOLUMAB VS. FOLFOX +/- NIVOLUMAB FOR FIRST-LINE TREATMENT OF METASTATIC HER2-NEGATIVE GASTROESOPHAGEAL ADENOCARCINOMA
A022101 (Radiation Therapy at MBMC Only)
A PRAGMATIC RANDOMIZED PHASE III TRIAL EVALUATING TOTAL ABLATIVE THERAPY FOR PATIENTS WITH LIMITED METASTATIC COLORECTAL CANCER: EVALUATING RADIATION, ABLATION, AND SURGERY [ERASUR]
